文献速递白内障与屈光手术角膜与眼表疾病

40岁以上近视患者ICL V4c植入后前晶状体密度的长期评估

Long-term evaluation of anterior lens density after implantable collamer lens V4c implantation in patients with myopia over 40 years old.
PubMed 文献 · Br J Ophthalmol · 2021-06-28

这项前瞻性研究纳入52例40岁以上近视患者共104眼,观察ICL V4c植入后42±7.1个月的安全性和有效性,并分析前晶状体密度变化。结果显示安全指数1.26±0.35、有效性指数0.91±0.41,前晶状体密度在0.5、1.0、1.5 mm处分别增加16.52%±10.46%、16.72%±9.85%、17.28%±11.93%。

要点

  • ICL V4c在40岁以上近视患者中显示长期安全性和有效性。
  • 随访42±7.1个月,前晶状体密度在各测量深度均有所增加。
  • 前晶状体密度变化可能与年龄和术前等效球镜度相关。

核心结论

  • ICL V4c在40岁以上人群中具有长期安全性和有效性。
  • 该类患者前晶状体密度增加,可能与年龄和等效球镜度有关。

研究设计与样本

  • 前瞻性研究纳入52例40岁以上近视患者共104眼,行ICL V4c植入。
  • 术前及术后1个月、3个月、3年记录等效球镜度、视力、眼压、内皮细胞密度、前房参数等。
  • 使用Pentacam HR分析瞳孔中心3 mm直径范围内0.5、1.0、1.5 mm深度的前晶状体密度变化。

主要发现

  • 总体随访42±7.1个月,末次随访安全指数为1.26±0.35,有效性指数为0.91±0.41。
  • 无眼丢失Snellen视力行,76%的眼最佳矫正远视力提高≥1行,62%的眼等效球镜度在±0.50 D以内。
  • 前晶状体密度在0.5、1、1.5 mm处分别增加16.52%±10.46%、16.72%±9.85%、17.28%±11.93%。
  • 术前、术后1个月和3个月的前晶状体密度与等效球镜度和年龄相关,末次随访时仅与年龄相关。
  • 前晶状体密度与其他参数均无相关性。

关键数值与推荐

  • 末次随访安全指数1.26±0.35,有效性指数0.91±0.41。
  • 76%的眼最佳矫正远视力提高≥1行,62%的眼等效球镜度在±0.50 D以内。
  • 前晶状体密度增加:0.5 mm处16.52%±10.46%,1 mm处16.72%±9.85%,1.5 mm处17.28%±11.93%。

临床怎么用

  • 对40岁以上近视患者行ICL V4c植入需关注长期前晶状体密度变化。
  • 术后随访中可将年龄和等效球镜度作为前晶状体密度变化的参考因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the long-term safety and efficacy of implantable collamer lens (ICL) V4c implantation and changes in the anterior lens density (ALD) in patients with myopia ≥40 years of age. METHODS: This prospective study included 104 eyes of 52 patients >40 years of age before ICL V4c implantation. Spherical equivalent (SE), uncorrected distance visual acuity, corrected distance visual acuity (CDVA), intraocular pressure, endothelial cell density, anterior chamber depth, anterior chamber volume and anterior chamber angle preoperatively, at 1 and 3 months, and at 3 years postoperatively were recorded. Pentacam HR was used to analyse ALD changes at a depth of 0.5, 1.0 and 1.5 mm within a 3 mm diameter range around the pupil's centre. RESULTS: The overall follow-up was uneventful at 42±7.1 months; the safety index at last follow-up was 1.26±0.35 and the efficacy index was 0.91±0.41. No eye lost the Snellen line of CDVA, 76% of the eyes had an increase in CDVA for ≥1 line and 62% had an SE within ±0.50 dioptre. The increase in ALD at 0.5, 1 and 1.5 mm was 16.52%±10.46%, 16.72%±9.85% and 17.28%±11.93%, respectively. Preoperative, 1-month and 3-month postoperative ALDs showed correlations with SE and age, and ALD at last follow-up was correlated only with age. There was no correlation between ALD and any other parameters. CONCLUSION: ICL V4c shows long-term safety and efficacy in people ≥40 years of age. ALD increased in such patients, which may be related to age and SE.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ye Y, Zhao J, Niu L, et al. Long-term evaluation of anterior lens density after implantable collamer lens V4c implantation in patients with myopia over 40 years old. Br J Ophthalmol. 2021. PMID: 34183326. doi:10.1136/bjophthalmol-2021-319205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。